Uricase from Bacillus fastidious loaded in alkaline enzymosomes: Enhanced biochemical and pharmacological characteristics in hypouricemic rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 82, Issue 1, 2012, Pages 43-48

  Tan, Qunyou ^a   Zhang, Jingqing ^b   Wang, Na ^b   Li, Xiaoling ^c   Xiong, Huarong ^b   Teng, Yongzhen ^b   He, Dan ^b   Wu, Jianyong ^b   Zhao, Chunjing ^b   Yin, Huafeng ^b   Zhang, Liangke ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Catalytic activity; Enzymosome; In vitro; Pharmacological characteristics; Uricase from Bacillus fastidious

Indexed keywords

URATE OXIDASE; URIC ACID;

ALKALINE ENZYMOSOME; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACILLUS; BACILLUS FASTIDIOUS; BIOCHEMISTRY; CATALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; ENCAPSULATION; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME MODIFICATION; HYPERURICEMIA; IN VITRO STUDY; LIPID VESICLE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL;

ANIMALS; BACILLUS; DISEASE MODELS, ANIMAL; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERURICEMIA; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; URATE OXIDASE; URIC ACID;

EID: 84866035581     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.06.002     Document Type: Article

References (37)

1. 2 S.P. Colowick, N.O. Kaplan, Methods in Enzymology Preparation and Assay of Enzymes vol. 2 1955 Academic Press London 485 489
2. H.M. Saeed, Y.R. Abdel-Fattah, Y.M. Gohar, and M.A. Elbaz Purification and characterization of extracellular Pseudomonas aeruginosa urate oxidase enzyme Pol. J. Microbiol. 53 2004 45 52
3. J.S. Bomalaski, and M.A. Clark Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase Curr. Rheumatol. Rep. 6 2004 240 247
4. G. Pasut, M. Sergi, and F.M. Veronese Anti-cancer PEG-enzymes: 30 years old, but still a current approach Adv. Drug Deliv. Rev. 60 2008 69 78
5. M.R. Sherman, M.G. Saifer, and F. Perez-Ruiz PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv. Drug Deliv. Rev. 60 1 2008 59 68
6. J.S. Bomalaski, F.W. Holtsberg, C.M. Ensor, and M.A. Clark Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies J. Rheumatol. 29 2002 1942 1949
7. D.S. Freitas, P.J. Spencer, R.C. Vassao, and J. Abrahao-Neto Biochemical and biopharmaceutical properties of PEGylated uricase Int. J. Pharm. 387 2010 215 222
8. J.A. O'Loughlin, J.M. Bruder, and M.J. Lysaght Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes ASAIO J. 50 2004 253 260
9. Y. Yasuda, T. Fujita, Y. Takakura, M. Hashida, and H. Sezaki Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol Chem. Pharm. Bull. 38 1990 2053 2056
10. G. Ihler, A. Lantzy, J. Purpura, and R.H. Glew Enzymatic degradation of uric acid by uricase-loaded human erythrocytes J. Clin. Invest. 56 1975 595 602
11. M. Magnani, U. Mancini, M. Bianchi, and A. Fazi Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation Adv. Exp. Med. Biol. 326 1992 189 194
12. Q.Y. Tan, N. Wang, H. Yang, L.K. Zhang, S. Liu, L. Chen, J. Liu, L. Zhang, N.N. Hu, C.J. Zhao, and J.Q. Zhang Characterization, stabilization and activity of uricase loaded in lipid vesicles Int. J. Pharm. 384 2010 165 172
13. G. Sessa, and G. Weissmann Incorporation of lysozyme into liposomes. A model for structure-linked latency J. Biol. Chem. 245 1970 3295 3301
14. M. Eugenia, M. Cruz, M.M. Gaspar, M. Barbara, F. Martins, and M.L. Corvo Liposomal superoxide dismutases and their use in the treatment of experimental arthritis D. Nejat, Methods in Enzymology, Liposomes vol. 391 2005 Academic Press London 395 413
15. M.M. Gaspar, R. Perez-Soler, and M.E. Cruz Biological characterization of l-asparaginase liposomal formulations Cancer Chemother. Pharmacol. 38 1996 373 377
16. M. Li, M.J. Hanford, J.W. Kim, and T.L. Peeples Amyloglucosidase enzymatic reactivity inside lipid vesicles J. Biol. Eng. 1 2007 4
17. M. Budai, P. Chapela, P. Gróf, A. Zimmer, M.E. Wales, J.R. Wild, I. Klebovich, I. Petrikovics, and M. Szilasi Physicochemical characterization of stealth liposomes encapsulating an organophosphate hydrolyzing enzyme J. Liposome Res. 19 2009 163 168
18. P. Walde, and S. Ichikawa Enzymes inside lipid vesicles: preparation, reactivity and applications Biomol. Eng. 18 2001 143 177
19. Q. Tan, J. Zhang, and L. Zhang Not only anticancer drugs but also enzymes can be encapsulated in either micelle or other carrier for the treatment of cancer Med. Hypotheses 74 2010 396 397
20. M. Yoshimoto Stabilization of enzymes through encapsulation in liposomes Methods Mol. Biol. 679 2011 9 18
21. Y. Nishida, N. Kamatani, and T. Miyamoto Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes J. Pharm. Pharmacol. 36 1984 354 355
22. M. Yoshimoto, Y. Miyazaki, Y. Kudo, K. Fukunaga, and K. Nakao Glucose oxidation catalyzed by liposomal glucose oxidase in the presence of catalase-containing liposomes Biotechnol. Prog. 22 2006 704 709
23. Y. Zhao, L. Zhao, G. Yang, J. Tao, Y. Bu, and F. Liao Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method Biotechnol. Appl. Biochem. 45 2006 75 80
24. Q.Y. Tan, N. Wang, H. Yang, L. Chen, H.R. Xiong, L.K. Zhang, J. Liu, C.J. Zhao, and J.Q. Zhang Preparation and characterization of lipid vesicles containing uricase Drug Deliv. 17 2010 28 37
25. J.Q. Zhang, J. Liu, X.L. Li, and B.R. Jasti Preparation and characterization of solid lipid nanoparticles containing silibinin Drug Deliv. 14 2007 381 387
26. O. Tiourina, T. Sharf, A. Balkina, M. Ollivon, A. Selischeva, G. Sorokoumova, and N.J. Larionova Interaction of the water-soluble protein aprotinin with liposomes: gel-filtration, turbidity studies, and 31P NMR studies Liposome Res. 13 2003 213 229
27. C.D. Georgiou, K. Grintzalis, G. Zervoudakis, and I. Papapostolou Mechanism of Coomassie brilliant blue G-250 binding to proteins: a hydrophobic assay for nanogram quantities of proteins Anal Bioanal. Chem. 391 2008 391 403
28. J.Q. Zhang, Z.R. Zhang, H. Yang, Q.Y. Tan, S.R. Qin, and X.L. Qiu Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies Pharm. Res. 22 2005 573 583
29. W. Huisinga, R. Telgmann, and M. Wulkow The virtual laboratory approach to pharmacokinetics: design principles and concepts Drug Discov. Today 11 2006 800 805
30. C. Zhang, X.L. Yang, J. Feng, Y.H. Yuan, X. Li, Y.Q. Bu, Y.L. Xie, H.D. Yuan, and F. Liao Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus Biosci. Biotechnol. Biochem. 74 2010 1298 1301
31. H. Nishimura, A. Matsushima, and Y. Inada Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity Enzyme 26 1981 49 53
32. R.H. Chen, A. Abuchowski, E.T. Van, N.C. Palczuk, and F.F. Davis Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol) Biochim. Biophys. Acta 660 1981 293 298
33. O. Schiavon, P. Caliceti, P. Ferruti, and F.M. Veronese Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(n- acryloylmorpholine) Farmaco 55 2000 264 269
34. P.P. Constantinides, M.V. Chaubal, and R. Shorr Advances in lipid nanodispersions for parenteral drug delivery and targeting Adv. Drug Deliv. Rev. 60 2008 757 767
35. M. Garg, T. Dutta, and N.K. Jain Reduced hepatic toxicity enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes Eur. J. Pharm. Biopharm. 67 2007 76 85
36. D.D. Lasic Novel applications of liposomes Trends Biotechnol. 16 1998 307 321
37. A. Volkl, E. Baumgart, and H.D. Fahimi Localization of urate oxidase in the crystalline cores of rat liver peroxisomes by immunocytochemistry and immunoblotting J. Histochem. Cytochem. 36 1988 329 336